- Home
- ORGO vs BBNX Comparison
ORGO vs BBNX Comparison
Compare ORGO & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- BBNX
- Stock Information
- Founded
- ORGO 1985
- BBNX 2015
- Country
- ORGO United States
- BBNX United States
- Employees
- ORGO N/A
- BBNX N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- ORGO Health Care
- BBNX Health Care
- Exchange
- ORGO Nasdaq
- BBNX Nasdaq
- Market Cap
- ORGO 620.3M
- BBNX 740.7M
- IPO Year
- ORGO N/A
- BBNX 2025
- Fundamental
- Price
- ORGO $4.92
- BBNX $25.69
- Analyst Decision
- ORGO Buy
- BBNX Strong Buy
- Analyst Count
- ORGO 2
- BBNX 10
- Target Price
- ORGO $7.50
- BBNX $24.40
- AVG Volume (30 Days)
- ORGO 729.3K
- BBNX 653.2K
- Earning Date
- ORGO 11-11-2025
- BBNX 11-06-2025
- Dividend Yield
- ORGO N/A
- BBNX N/A
- EPS Growth
- ORGO N/A
- BBNX N/A
- EPS
- ORGO N/A
- BBNX N/A
- Revenue
- ORGO $429,531,000.00
- BBNX $69,830,000.00
- Revenue This Year
- ORGO $2.57
- BBNX $42.80
- Revenue Next Year
- ORGO $9.80
- BBNX $34.58
- P/E Ratio
- ORGO N/A
- BBNX N/A
- Revenue Growth
- ORGO N/A
- BBNX 38911.17
- 52 Week Low
- ORGO $2.48
- BBNX $8.89
- 52 Week High
- ORGO $6.71
- BBNX $25.63
- Technical
- Relative Strength Index (RSI)
- ORGO 54.02
- BBNX 84.22
- Support Level
- ORGO $4.75
- BBNX $18.12
- Resistance Level
- ORGO $5.10
- BBNX $19.32
- Average True Range (ATR)
- ORGO 0.21
- BBNX 1.30
- MACD
- ORGO -0.01
- BBNX 0.70
- Stochastic Oscillator
- ORGO 51.40
- BBNX 97.40
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.